deutetrabenazine
deutetrabenazine: sourced relationships with 1 company · 2 clinical trials tracked · 2 FDA decisions.
deutetrabenazine evidence translation
What we can confirm
2 FDA records · 2 tracked trials
What it means
What to watch
Prepared research question
How could deutetrabenazine → TEVA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Teva Pharmaceutical Industries Limited (TEVA) Reported 2023-02-17 · Current development: unknownSource Huntington's Disease | Phase 4 |
| Teva Pharmaceutical Industries Limited (TEVA) Reported 2023-02-17 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (2)
Identification, Assessment, and Treatment of Tardive Dyskinesia With Deutetrabenazine in Adults With Intellectual/Developmental Disabilities and Co-occurring Psychiatric and/or Behavioral Disorders
Primary endpoint: Change in AIMS total scores of items 1-7
Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Chorea Associated With Huntington's Disease.
Primary endpoint: Change From Baseline in TMC Score in Participants Receiving ≥24 mg/Day
FDA Decisions2 records
Frequently asked questions
Which companies have sourced relationships with deutetrabenazine?
deutetrabenazine has dated SEC/FDA relationship records for Teva Pharmaceutical Industries Limited.
How many clinical trials involve deutetrabenazine?
BioSniper tracks 2 clinical trials involving deutetrabenazine.
What is deutetrabenazine's latest FDA decision?
The most recent tracked FDA decision for deutetrabenazine is Approval, dated February 17, 2023.